U.S. Software Stock News

BigBear.ai Holdings (BBAI) has been on a wild ride, with the stock up roughly 55% year to date and more than 150% over the past year, despite lingering net losses. See our latest analysis for BigBear.ai Holdings. The recent pullback, including a 1 month share price return of minus 11.0 percent from a 90 day gain of 26.1 percent and a standout 3 year total shareholder return of 678.1 percent, suggests momentum is cooling, but the longer term narrative remains powerful. If BigBear.ai has you...

Rapid expansion is the big story for Dutch Bros (BROS) right now, with new drive thru shops planned across Louisiana, Florida, Tennessee, and Ohio, and rising same store sales backing up that growth. See our latest analysis for Dutch Bros. That expansion story is increasingly reflected in the market, with the share price at $61.16, an 8.61% year to date share price return and a powerful 98.44% three year total shareholder return suggesting momentum is still building rather than fading. If...

Earlier this week, Oracle reported fiscal Q2 2026 results showing revenue of US$16.06 billion and net income of US$6.14 billion, alongside a sharp increase in AI‑driven cloud infrastructure backlog and a quarterly dividend declaration of US$0.50 per share. At the same time, Oracle’s decision to lift its fiscal 2026 capital expenditure plan to about US$50 billion, largely to fund AI data centers for customers such as OpenAI, Meta, and Nvidia, has intensified concerns about its growing debt...

Wondering if Apellis Pharmaceuticals is finally offering real value at today’s price, or if it is just another biotech value trap in disguise, you are not alone. The stock has jumped 6.8% over the last week and 26.0% over the past month, even though it is still down 23.9% year to date and 24.0% over the past year. This tells you sentiment has started to shift, but long-term holders may still be underwater. That recent surge has been driven largely by improving confidence in the commercial...

General Dynamics (GD) has quietly cooled off after a strong run this year, slipping about 3% over the past month even as its year to date gain still sits near 29%. See our latest analysis for General Dynamics. At around $337.49 per share, General Dynamics has eased back from recent highs. That softer 30 day share price return comes after a powerful year to date climb, with longer term total shareholder returns still suggesting momentum is cooling rather than collapsing. If you are reassessing...

If you are wondering whether Micron Technology is still a smart buy after its massive run up, or if the easy money has already been made, you are in the right place. The stock has surged 176.1% year to date and 136.2% over the last year. This comes even with a small 1.5% pullback in the past month and a 1.7% gain over the last week, which hints that investor expectations and perceived risk are shifting fast. Recent headlines have zeroed in on Micron as a key beneficiary of demand for high...

Concentrix (CNXC) just checked two big boxes for investors, advancing its Webhelp integration while locking in top tier AI governance certifications, and together these moves are quietly reshaping how the market views its story. See our latest analysis for Concentrix. Even with the Webhelp integration progressing and fresh AI certifications in hand, Concentrix is still trying to win back trust. Its 11.9% 1 month share price return contrasts sharply with a much weaker 3 year total shareholder...

In early December 2025, Iridium Communications declared a US$0.15 per share cash dividend payable on December 31 and added experienced telecom and cloud executive Louis Alterman to its expanded 12-member board, while HD Hyundai Construction Equipment selected Iridium to power global satellite connectivity for its Hi MATE remote fleet management system. Together, the Hyundai partnership and governance changes highlight Iridium’s push deeper into industrial IoT and enterprise mobility,...

Wondering if Western Midstream Partners is still good value after such a big multi year run? This article will walk through whether the current price makes sense or if the market is getting ahead of itself. After climbing an impressive 313.7% over 5 years and 97.3% over 3 years, the units have cooled lately, with a 1 year gain of 8.8%, a modest 0.4% return year to date, a 1.3% rise over 30 days, and a slight 1.5% dip in the last week. Recent headlines have focused on Western Midstream...

Q4 earnings turn profitable as full year stays in the red Quanex Building Products (NX) just posted a profitable fourth quarter while still closing fiscal 2025 with a sizable net loss and cautious, flat guidance for 2026, a mix that has investors reassessing the stock. See our latest analysis for Quanex Building Products. The upbeat fourth quarter has sparked a sharp near term reset in sentiment, with a 1 month share price return of 25.34 percent and a 7 day gain of 19.28 percent. However,...

Energy Transfer (ET) has quietly slid this year, with the unit price down about 16% year to date even as the partnership continues to post growing revenue and double digit net income gains. See our latest analysis for Energy Transfer. That slide reflects fading near term momentum, with a year to date share price return of negative 15.98 percent, even though the five year total shareholder return sits at a hefty 263.47 percent. If Energy Transfer’s pullback has you thinking about where else...

Core & Main (CNM) just checked several important boxes for investors, delivering steady third quarter growth, reaffirming its full year outlook, and leaning into acquisitions, buybacks, and expansion in Canada. See our latest analysis for Core & Main. That mix of steady execution and bolder moves on M&A and buybacks has helped CNM rebound, with a 7 day share price return of 11.67% and a powerful three year total shareholder return of 182.14%, suggesting momentum is rebuilding after earlier...

ProPetro Holding Corp. recently announced that its PROPWR division signed a contract with a Coterra Energy subsidiary to develop and install distributed microgrids across the New Mexico Permian Basin, lifting committed capacity to over 220 megawatts and prompting higher 2026 capital expenditure guidance of US$250 million to US$275 million. This move accelerates PROPWR’s push toward a one-gigawatt portfolio by 2030 and underscores a shift toward longer-term, power-focused contracts that could...

Elevance Health (ELV) is leaning into digital tools with its expanded Virtual Assistant, now reaching 22 million commercial members and aiming to simplify everything from coverage questions to cost estimates in real time. See our latest analysis for Elevance Health. Those digital moves, alongside Elevance Health's board refresh with Amy Schulman joining as an independent director, come as momentum has quietly improved, with a 90 day share price return of 15.18 percent contrasting with a three...

Valuation backdrop and recent performance Sempra (SRE) has quietly slipped about 4 % over the past month even as its past 3 months return remains positive, creating an interesting setup for investors watching regulated utility names. See our latest analysis for Sempra. At around $88.49, Sempra’s recent 7 day and 30 day share price declines contrast with a modestly positive year to date share price return and solid multi year total shareholder returns. This suggests momentum has cooled, while...

Why Coca-Cola Stock Is Back on Investors Radar Coca-Cola (KO) has quietly outperformed the wider market over the past year, and with the stock up about 5% in the past 3 months, investors are revisiting its long term appeal. See our latest analysis for Coca-Cola. The latest move takes Coca-Cola's share price to $70.52, and that steady upward drift, alongside a roughly 15% one year total shareholder return, suggests resilient momentum as investors lean into its dependable earnings and dividend...

If you are wondering whether Arcutis Biotherapeutics is still a smart bet after its big run, or if most of the upside is already priced in, you are not alone. That is exactly what we are going to unpack. The stock has pulled back about 7.0% over the last week, but that comes after a sharp 23.8% gain in the past month and a 99.3% rise year to date, with a 128.7% return over the last year that has completely changed how the market looks at this name. Those moves have been fueled by a series of...

Visa (V) shares are quietly grinding higher, adding about 0.6% today and roughly 5% over the past week, as investors lean into its steady double digit earnings growth and resilient payment volumes. See our latest analysis for Visa. That steady climb sits on top of a solid backdrop, with the share price now at $347.83 and Visa posting a double digit year to date share price return. Longer term total shareholder returns signal durable compounding, suggesting momentum is still building rather...

International Business Machines (IBM) has climbed roughly 22% over the past 3 months and more than 40% year to date, a move that has investors rethinking how this old-guard tech name is being valued. See our latest analysis for International Business Machines. That surge has not come out of nowhere, with investors rewarding steady cloud and AI execution as recent earnings and guidance resets have shifted the narrative toward profitable growth. Even after short term share price wobbles, IBM’s...

USA Rare Earth (USAR) has been catching more investor attention lately as its share price climbed over the past year while many small cap miners struggled. The key question now is whether that momentum is justified. See our latest analysis for USA Rare Earth. That recent pullback to a $17.04 share price comes after a strong run, with a roughly 38 percent year to date share price return and a 35 percent one year total shareholder return. This suggests momentum is still broadly intact as...

Earlier this month, Tenaya Therapeutics reported that the FDA lifted the clinical hold on its MyPEAK-1 Phase 1b/2a trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and released encouraging interim Phase 1b/2 data for TN-401 in arrhythmogenic right ventricular cardiomyopathy, while also completing a US$60,000,000 composite units offering. Together, the resumed TN-201 trial and early TN-401 signals highlight Tenaya’s push to use AAV9-based gene therapies to address inherited...

Wondering if Netflix is still worth your money after its rollercoaster run, or if the real upside has already been priced in? You are not alone. This is exactly the kind of stock where valuation matters most. The share price has pulled back recently, down about 5.0% over the last week and 17.8% over the past month. Yet it is still up 7.3% year to date and 3.6% over the last year, with a 227.4% gain over three years and 78.1% over five years reminding investors how powerful this name can be...

Loews (L) has been getting more investor attention lately, and it is not just sentiment. Recent updates show steady revenue and earnings growth, helped by stronger results at majority owned CNA Financial. See our latest analysis for Loews. Those solid fundamentals seem to be filtering through to sentiment, with Loews’ recent governance tweaks and legal clarity arriving alongside a strong year to date. The share price return is up sharply while multi year total shareholder returns remain very...

If you are wondering whether Boston Scientific at around $92 a share is still a smart buy or if the big gains are already behind it, this breakdown is for you. The stock has slipped about 5.1% over the last week and 11.1% over the past month, but it is still up 3.6% year to date and 102.1% over three years and 161.2% over five years, which highlights its longer term momentum. Recent headlines have focused on Boston Scientific's continued expansion in minimally invasive cardiovascular and...